Curevac Doesn't Rule Out Accelerated Approval For COVID-19 Vaccine


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ curevac-doesnt-accelerated-approval-covid19-vaccine
CureVac, backed by Microsoft founder and billionaire Bill Gates, listed on the Nasdaq stock market on Friday, raising $213 million.

German biotechnology firm CureVac doesn't preclude a fast endorsement process for its planned immunization against COVID-19, its CEO was cited as saying on Sunday.

The organization said on Friday that it hopes to put its antibody available by mid-2021. Acquiring fast endorsement recommends the organization is pushing for a previous delivery date even though CEO Franz-Werner Haas didn't give any subtleties on how likely this was.

"We are not precluding quickened endorsement, however, this must be accomplished in close participation with the specialists," Haas told the Boerse Online monetary site.

CureVac, sponsored by Microsoft originator and extremely rich person Bill Gates, recorded on the Nasdaq financial exchange on Friday, raising $213 million.

The aftereffects of the as of late began clinical preliminaries of the organization's forthcoming antibody are to be distributed in harvest time, Haas stated, emphasizing that right now endorsement was normal in the main portion of one year from now.

CureVac is investigating how to utilize particles conveying a particular hereditary code called courier RNA (mRNA) to treat a progression of infections, including COVID-19.

By utilizing courier RNA, analysts trust they can force a patient's own body to make proteins that can assume a significant job in battling sickness.

"We see a more profound and more extensive comprehension in the United States that the mRNA innovation we use can rapidly build up a viable and productive immunization," Haas said.

Tags : #Curevac #Germany #COVID-19

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026